Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Last trade $3.80
Day change -$0.01 (-0.26%)
Day range $3.78 – $4.07
Volume 417,639
Market cap $230M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$230.39M
Price / earnings
—
Price / book
1.15×
Price / sales
1×
EV / sales
0.74×
EV / EBITDA
-1.01×

Profitability

Earnings per share
-$4.54
Return on assets
-71.88%
Return on equity
-137.51%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
1.54×
Quick ratio
1.53×
Cash ratio
0.4×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$139.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VNDA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$69.82M$50.53M$51.72M$57.22M$56.26M$52.59M$50.04M$53.19M
Cost of revenue$4.15M$3.56M$3.16M$3.83M$2.95M$2.74M$3.52M$2.59M
Gross profit$65.66M$46.97M$48.56M$53.38M$53.3M$49.85M$46.52M$50.6M
Selling, general and administrative$59.58M$71.84M$68.36M$62.98M$60.27M$64.62M$50.08M$39.28M
Research and development$27.62M$36.95M$28.44M$29.01M$22.56M$21.99M$35.71M$19.84M
Total operating expenses$89.18M$110.78M$98.78M$93.74M$84.59M$88.36M$87.55M$60.87M
Operating income-$23.52M-$63.81M-$50.22M-$40.35M-$31.28M-$38.5M-$41.03M-$10.28M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$22.39M-$62.38M-$48.42M-$38M-$28.39M-$34.89M-$37.37M-$6.5M
Income taxes$174K$129K$143K$103.19M-$5.8M-$7.68M-$7.87M-$1.59M
Net income-$22.56M-$62.51M-$48.57M-$141.19M-$22.59M-$27.21M-$29.49M-$4.91M
Net income attributable to common shareholders-$22.56M-$62.51M-$48.57M-$141.19M-$22.59M-$27.21M-$29.49M-$4.91M
EBITDA-$21.29M-$61.56M-$47.96M-$38.3M-$29.23M-$36.49M-$39.05M-$8.31M
Basic earnings per share-$0.37-$1.04-$0.82-$2.39-$0.38-$0.46-$0.50-$0.08
Diluted earnings per share-$0.37-$1.04-$0.82-$2.39-$0.38-$0.46-$0.50-$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?

Fortrea Holdings Inc. (FTRE) is expected to report Q3 2026 earnings of $0.24 per share, representing 100% year-over-year growth, though revenues are projected to decline 4.4%. With a negative Earnings ESP of -10.35% and Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 2 of the last 4 quarters.

Zacks Investment Research

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.

Benzinga

Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report

U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with several individual stocks showing significant moves based on company announcements and FDA approvals.

The Motley Fool

Vanda (VNDA) Q2 Revenue Rises 4%

Vanda Pharmaceuticals reported a Q2 2025 net loss of $27.2 million, with revenue rising 4% to $52.6 million. Fanapt® showed strong sales growth, while HETLIOZ® and PONVORY® experienced declines. The company continues to invest in its product pipeline and expand market reach.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.